CoChat
Sign Up
Cited by 967Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Open access
Peggs, Karl S., Quezada, Sergio A., Chambers, Cynthia A., Korman, Alan J., Allison, James P.·2009·Journal of Experimental Medicine
DOI 10.1084/jem.20082492PMC PMC2722174
Open this paper in CoChat — free accountOpen PDF

Abstract

Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central regulatory role led to the development of antibodies designed to block CTLA-4 activity in vivo, aiming to enhance immune responses against cancer. Despite their preclinical efficacy and promising clinical activity against late stage metastatic melanoma, the critical cellular targets for their activity remains unclear. In particular, debate has focused on whether the effector T cell (Teff) or regulatory T cell (T reg cell) compartment is the primary target of antibody-mediated blockade. We developed a mouse expressing human instead of mouse CTLA-4, allowing us to evaluate the independent contributions of CTLA-4 blockade of each T cell compartment during cancer immunotherapy in an in vivo model of mouse melanoma. The data show that although blockade on effector cells significantly improves tumor protection, unicompartmental blockade on regulatory cells completely fails to enhance antitumor responses. However, concomitant blockade of both compartments leads to a synergistic effect and maximal antitumor activity. We conclude that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–CTLA-4 antibodies during cancer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20082492

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Functional replacement of mouse CTLA-4 with the human CTLA-4 gene in vivo. (a and b) Flow cytometric analysis of intracellular Foxp3 and CTLA-4 in freshly isolated LN CD4+ T cells from WT and HuTg mice, labeled with aMUCTLA-4 (a) and aHuCTLA-4 (b). (c) Absolute CD4+Foxp3+, CD4+Foxp3−, and CD8+ T cell counts from age-matched WT (empty circles) and HuTg mice (filled circles; 8–10-mo-old mice; n = 8–9 per group). (d) Frequency of Ki67-expressing CD4+Foxp3+, CD4+Foxp3−, and CD8+ T cells in LN of WT (empty circles) and HuTg mice (filled circles). (e) Absolute cell counts for B cell, NK cell, and dendritic cell populations in LN of WT (empty circles) and HuTg mice (filled circles). Data represent three independent experiments. Horizontal bars in c–e represent mean values.
Figure 1. Functional replacement of mouse CTLA-4 with the human CTLA-4 gene in vivo. (a and b) Flow cytometric analysis of intracellular Foxp3 and CTLA-4 in freshly isolated LN CD4+ T cells from WT and HuTg mice, labeled with aMUCTLA-4 (a) and aHuCTLA-4 (b). (c) Absolute CD4+Foxp3+, CD4+Foxp3−, and CD8+ T cell counts from age-matched WT (empty circles) and HuTg mice (filled circles; 8–10-mo-old mice; n = 8–9 per group). (d) Frequency of Ki67-expressing CD4+Foxp3+, CD4+Foxp3−, and CD8+ T cells in LN of WT (empty circles) and HuTg mice (filled circles). (e) Absolute cell counts for B cell, NK cell, and dendritic cell populations in LN of WT (empty circles) and HuTg mice (filled circles). Data represent three independent experiments. Horizontal bars in c–e represent mean values.CC BY-NC-SA · PubMed Central
Figure 2. Unicompartmental blockade with aMuCTLA-4 during in vitro suppressor assays suggests both cell autonomous and non–cell autonomous activities of CTLA-4. Suppressor assays were performed using mixtures of WT and HuTg cells. (a and b) Proliferation of 50,000 purified WT or HuTg CD4+CD25− and CD4+CD25+ T cells in response to T cell–depleted splenocytes and anti-CD3 and in the presence of control IgG or aMuCTLA-4, confirming the species specificity of the CTLA-4 blockade. (c) Unicompartmental blockade of 50,000 WT CD4+CD25− T cells with aMuCTLA-4, compared with control IgG during in vitro suppression by addition of increasing numbers of HuTg CD4+CD25+ T reg cells. (d) Unicompartmental blockade of WT CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppression of 50,000 HuTg CD4+CD25− T cells. (e) Bicompartmental blockade of both WT CD4+CD25− Teff and CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppressor assays. Data in a–e represent three or more independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.
Figure 2. Unicompartmental blockade with aMuCTLA-4 during in vitro suppressor assays suggests both cell autonomous and non–cell autonomous activities of CTLA-4. Suppressor assays were performed using mixtures of WT and HuTg cells. (a and b) Proliferation of 50,000 purified WT or HuTg CD4+CD25− and CD4+CD25+ T cells in response to T cell–depleted splenocytes and anti-CD3 and in the presence of control IgG or aMuCTLA-4, confirming the species specificity of the CTLA-4 blockade. (c) Unicompartmental blockade of 50,000 WT CD4+CD25− T cells with aMuCTLA-4, compared with control IgG during in vitro suppression by addition of increasing numbers of HuTg CD4+CD25+ T reg cells. (d) Unicompartmental blockade of WT CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppression of 50,000 HuTg CD4+CD25− T cells. (e) Bicompartmental blockade of both WT CD4+CD25− Teff and CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppressor assays. Data in a–e represent three or more independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.CC BY-NC-SA · PubMed Central
Figure 3. CTLA-4−/− T reg cell display diminished regulatory activity during in vitro suppressor assays. Suppressor assays were performed using mixtures of WT and CTLA-4−/− cells. (a) Proliferation of WT and CTLA-4−/− CD4+CD25− and CD4+CD25+ T cells in response to T cell–depleted splenocytes and anti-CD3, demonstrating cell autonomous inhibitory function of CTLA-4 in the proliferation of Teff and T reg cells. (b) Suppression of 50,000 WT or CTLA-4−/− CD4+CD25− Teff cells by increasing numbers of WT CD4+CD25+ T reg cells. (c) Suppression of 50,000 WT CD4+CD25− Teff cells by increasing numbers of WT or CTLA-4−/− CD4+CD25+ T reg cells. (d) Suppression of 50,000 CTLA-4−/− CD4+CD25− T cells by WT or CTLA-4−/− CD4+CD25+ T reg cells. Data in a–d represent three independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.
Figure 3. CTLA-4−/− T reg cell display diminished regulatory activity during in vitro suppressor assays. Suppressor assays were performed using mixtures of WT and CTLA-4−/− cells. (a) Proliferation of WT and CTLA-4−/− CD4+CD25− and CD4+CD25+ T cells in response to T cell–depleted splenocytes and anti-CD3, demonstrating cell autonomous inhibitory function of CTLA-4 in the proliferation of Teff and T reg cells. (b) Suppression of 50,000 WT or CTLA-4−/− CD4+CD25− Teff cells by increasing numbers of WT CD4+CD25+ T reg cells. (c) Suppression of 50,000 WT CD4+CD25− Teff cells by increasing numbers of WT or CTLA-4−/− CD4+CD25+ T reg cells. (d) Suppression of 50,000 CTLA-4−/− CD4+CD25− T cells by WT or CTLA-4−/− CD4+CD25+ T reg cells. Data in a–d represent three independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.CC BY-NC-SA · PubMed Central
Figure 4. CTLA-4 blockade of effector and regulatory compartments synergizes to produce maximal antitumor activity. (a) Experimental design. RAG2-deficient mice were reconstituted with four combinations of WT and HuTg T reg and non–T reg (CD4+ and CD8+) cells. 10 wk later, they were challenged with 20 × 103 B16/BL6 melanoma cells intradermally. From day 3, they received combination immunotherapy with Gvax and aMuCTLA-4. (b) Tumor growth curves for mice reconstituted with WT Teff and T reg cells (red), HuTg Teff and WT T reg cells (green), WT Teff and HuTg T reg cells (black), and HuTg Teff and T reg cells (blue; n = 10 per group). Error bars indicate SEM. Data represent three independent experiments. (c) Survival curves with color coding as in b. Mice were euthanized when tumor volume exceeded 350 mm3. Pooled results from three independent experiments are shown.
Figure 4. CTLA-4 blockade of effector and regulatory compartments synergizes to produce maximal antitumor activity. (a) Experimental design. RAG2-deficient mice were reconstituted with four combinations of WT and HuTg T reg and non–T reg (CD4+ and CD8+) cells. 10 wk later, they were challenged with 20 × 103 B16/BL6 melanoma cells intradermally. From day 3, they received combination immunotherapy with Gvax and aMuCTLA-4. (b) Tumor growth curves for mice reconstituted with WT Teff and T reg cells (red), HuTg Teff and WT T reg cells (green), WT Teff and HuTg T reg cells (black), and HuTg Teff and T reg cells (blue; n = 10 per group). Error bars indicate SEM. Data represent three independent experiments. (c) Survival curves with color coding as in b. Mice were euthanized when tumor volume exceeded 350 mm3. Pooled results from three independent experiments are shown.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

Sorted by citations

Items 101–200 of 967

Related

See all

Metadata

Authors
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Massachusetts Chan Medical School (US)
  • Medarex, Inc., Milpitas, CA 95035 3
Corresponding author
Allison, James P.
ORCID
Venue
Journal of Experimental Medicine
Publisher
Rockefeller University Press
Published
2009-07-06
Volume
206
Issue
8
Pages
1717-1725
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
DOI
10.1084/jem.20082492
PMC
PMC2722174
OpenAlex
W2013043293
Cited by
967
References
34
Citations by year
2026: 17 · 2025: 46 · 2024: 57 · 2023: 56 · 2022: 51 · 2021: 54 · 2020: 59 · 2019: 64 · 2018: 78 · 2017: 82 · 2016: 78 · 2015: 81 · 2014: 56 · 2013: 60 · 2012: 39
FWCI
20.80
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • Cancer Research Institute
  • Bristol-Myers Squibb
  • Memorial Sloan-Kettering Cancer Center
  • University College London
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CTLA-4, anti-CTLA-4 antibody, regulatory T cells, effector T cells, cancer immunotherapy, melanoma, immune checkpoint blockade, humanized mice, antitumor immunity, T cell tolerance
MeSH terms
Animals, Antibodies, Neoplasm, Humans, Immunosuppression Therapy, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Transgenic, Recombinant Proteins, Antigens, CD, T-Lymphocyte Subsets, Mice, Knockout, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review